Kiniksa Pharmaceuticals, Ltd. KNSA 深 滬
已收盤 02-06 16:00:00 美东时间
43.09
+0.510
+1.20%
華盛通- 最 高43.74
- 今 開42.77
- 成交量 31.28万股
- 最 低 42.69
- 昨 收 42.58
- 總市值 32.66亿
- 52周最高 45.50
- 市盈率 靜 --
- 換手率 0.41%
- 52周最低 18.255
- 委 比 57.49%
- 總股本 7579.58万
- 歷史最高 45.50
- 量 比 0.59
- 振 幅 2.47%
- 歷史最低 5.01
- 每 手 1
- 風險率 7.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $50
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $48 to $50.
01-13 21:53
Kiniksa Reports ARCALYST 2025 Net Product Revenue Of $677.5M, Up ~62% YoY, And Guides 2026 Revenue Of $900M–$920M While Advancing IL-1 Pipeline
ARCALYST (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2 recurrent
01-12 20:53
Kiniksa Pharmaceuticals Provides Corporate Update
Kiniksa Pharmaceuticals reported ARCALYST net product revenue of $677.5 million in 2025, up 62% from 2024. 2026 revenue is expected to reach $900-$920 million. KPL-387 Phase 2 data is anticipated in H2 2026, while KPL-1161 Phase 1 trials aim to begin by year-end. Cash balance rose to $414.1 million in 2025, supporting ongoing efforts and future opportunities.
01-12 12:30
Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 2:15 p.m. PT (5:15 p.m. ET). A live webcast and replay of the presentation will be available via the company’s website. Kiniksa focuses on developing novel therapies for unmet medical needs, particularly in cardiovascular diseases.
01-07 21:01
Kiniksa Pharmaceuticals (KNSA) Receives a Buy from Jefferies
Jefferies analyst Roger Song maintained a Buy rating on Kiniksa Pharmaceuticals...
2025-11-18 22:26
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
2025-10-30 14:22
Kiniksa Expects 2025 Arcalyst Net Product Revenue Of $670M-$675M Compared To Prior Guidance Of $625M-$640M
Kiniksa expects its current operating plan to remain cash flow positive on an annual basis.
2025-10-28 19:43
Earnings Scheduled For October 28, 2025
Companies Reporting Before The Bell • PayPal Holdings (NASDAQ:PYPL) is expected...
2025-10-28 19:11
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
Kiniksa Pharmaceuticals reported strong Q3 2025 results with ARCALYST net product revenue reaching $180.9 million, up 61% year-over-year, and raised its 2025 net product revenue guidance to $670-$675 million. KPL-387 received Orphan Drug Designation for pericarditis, and cash rose by $44.3 million to $352.1 million. The company plans a conference call to discuss these results.
2025-10-28 11:30
